IP Library Granted Patent US 11,433,048
Granted Patent B2
US 11,433,048 · App. 16/310,149 · Granted Sep 6, 2022

CXCR4 receptor-binding compounds useful for increasing interferon level

Inventors: Nicolas Pietrancosta (Paris, FR); Nikaïa Smith (Nice, FR); Jean-Philippe Herbeuval (Paris, FR)
A61K31/395A61K31/417A61K31/4164A61K31/4709A61K31/4725G01N33/566G01N33/6866G16B35/20G16C20/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,048
App. No.
16/310,149
Granted
Sep 6, 2022
Kind
B2
Abstract

The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).

Claims (7)

1. A method for increasing or restoring interferon (IFN) level in an individual in need thereof, the method comprising administering to the individual a CXCR4 receptor-binding compound, wherein the interferon is a type-I interferon (IFN-I), and wherein the CXCR4 receptor-binding compound is plerixafor.

2. The method according to claim 1 , wherein the CXCR4 receptor-binding compound interacts with at least 6 amino acids of a CXCR4 receptor represented by SEQ ID NO: 1, wherein the amino acids are selected from the group consisting of alanine 175, aspartic acid 171, aspartic acid 262, phenylalanine 174, valine 196, glycine 207, tyrosine 255, tyrosine 256, isoleucine 259, serine 263 and glutamic acid 288.

3. The method according to claim 1 , wherein the interferon (INF) is IFN-α and/or IFN-β.

4. The method according to claim 1 , for increasing or restoring IFN secretion by immune cells.

5. The method according to claim 1 , for increasing or restoring IFN secretion by immune cells selected from the group consisting of plasmacytoid dendritic cells, monocytes and NK cells.

6. The method according to claim 1 , for preventing or treating a disease selected from the group consisting of a viral infection, an opportunistic infection, allergy, rheumatoid arthritis, multiple sclerosis, a cancer with an overproduction of spermine, depression-induced immunosuppression and diabetes.

7. A method for increasing or restoring type-I IFN secretion by immune cells comprising the in vitro use of a CXCR4 receptor-binding compound as defined in claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2022
From: PIETRANCOSTA, NICOLAS; SMITH, NIKAÏA; HERBEUVAL, JEAN-PHILIPPE
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PARIS DESCARTES
Reel/Frame 060722/0517 →
CHANGE OF NAME Recorded May 12, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059988/0388 →
MERGER Recorded May 12, 2022
From: UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 060044/0856 →